Akademik Veri Yönetim Sistemi
European Radiology, cilt.24, sa.1, ss.184-190, 2014 (SCI-Expanded, Scopus)
Objectives: To determine the frequency of and possible factors related to contrast-induced nephropathy (CIN) in hospitalised patients with cancer. Methods: Ninety adult patients were enrolled. Patients with risk factors for acute renal failure were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum creatinine (Cr) of 0.5 mg/dl or more, or elevation of Cr to 25% over baseline. Relationships between CIN and possible risk factors were investigated. Results: CIN was detected in 18/90 (20%) patients. CIN developed in 25.5% patients who underwent chemotherapy and in 11% patients who did not (P =0.1). CIN more frequently developed in patients who had undergone CT within 45 days after the last chemotherapy (P= 0.005); it was also an independent risk factor (P =0.017). CIN was significantly more after treatment with bevacizumab/irinotecan (P=0.021) and in patients with hypertension (P=0.044). Conclusions: The incidence of CIN after CT in hospitalised oncological patientswas 20%. CIN developed 4.5-times more frequently in patients with cancer who had undergone recent chemotherapy. Hypertension and the combination of bevacizumab/irinotecan may be additional risk factors for CIN development. Key Points: • Contrast-induced nephropathy (CIN) is a concern for oncological patients undergoing CT. • CIN occurs more often when CT is performed <45 days after chemotherapy. • Hypertension and treatment with bevacizumab appear to be additional risk factors. © European Society of Radiology 2013.